Amyotrophic Lateral Sclerosis Market Size, Share, Growth and Trends, Report 2024-2031

The Global Amyotrophic Lateral Sclerosis Market size reached USD 0.7 billion in 2023 and is projected to witness lucrative growth by reaching up to USD 1.0 billion by 2031. The global amyotrophic lateral sclerosis market is expected to exhibit a CAGR of 5.1% during the forecast period (2024-2031).

The Amyotrophic Lateral Sclerosis (ALS) market is focused on providing therapies to help manage symptoms and slow the progression of this debilitating condition, often known as Lou Gehrig's disease. Treatment options range from medications and assistive devices to comprehensive supportive care. Researchers are continuously exploring new ways to improve patient outcomes, with ongoing efforts aimed at discovering innovative treatments that could potentially modify the disease and enhance the overall quality of life for those affected by ALS.

Get a Free Sample Research PDF - https://www.datamintelligence.com/download-sample/amyotrophic-lateral-sclerosis-market

Key Developments:

• On June 14, 2023, Coya Therapeutics, Inc., a clinical-stage biotech company focused on developing biologics to enhance Treg function, welcomed Dr. Michelle Frazier, Ph.D., to its leadership team as Senior Vice President of Regulatory Affairs. Dr. Frazier brings significant regulatory and Chemistry, Manufacturing, and Controls (CMC) expertise and will oversee all of Coya's regulatory submissions, including the upcoming Investigational New Drug (IND) submission for COYA 302, a potential treatment for Amyotrophic Lateral Sclerosis (ALS).

• In related ALS news, on May 17, 2023, PatientsLikeMe (PLM), a digital platform that supports over 850,000 patients, announced a partnership with the Neurological Clinical Research Institute (NCRI) at Massachusetts General Hospital (MGH). This collaboration was unveiled at the 2nd Annual ALS Drug Development Summit and involves sharing de-identified patient data to enhance ALS research. PLM's data will now be part of the Pooled Resource Open-Access ALS Clinical Trials (PRO-ACT) database, alongside anonymized information from 29 clinical trials and 11,685 patient records. Both datasets will be hosted and maintained by the NCRI, offering valuable resources for the global research community.

• Additionally, on June 2, 2023, CureALS, a nonprofit organization focused on combating ALS and other neurodegenerative diseases like Alzheimer's, Parkinson's, and Frontotemporal Dementia, officially launched. Founded by former NCR Chairman and CEO Bill Nuti, who retired in 2018 after being diagnosed with ALS, CureALS aims to revolutionize research through public/private partnerships, data sharing, and the use of AI technology to advance the fight against these challenging diseases.

Market Dynamics:

Advancements in Research and Developments Drive the Growth of the Amyotrophic Lateral Sclerosis Market

Recent advancements in research and development have led to the creation of innovative therapies for Amyotrophic Lateral Sclerosis (ALS). These include gene therapy, stem cell therapy, and neuroprotective agents, all of which aim to slow disease progression, enhance symptom management, and potentially modify the course of the disease. The introduction of these cutting-edge treatments is expanding the range of options available to ALS patients and driving growth in the market.

Ongoing research continues to focus on understanding the underlying causes, genetic factors, and mechanisms of ALS progression. These efforts are helping researchers discover new therapeutic targets and develop more effective treatment approaches. A notable milestone occurred on April 25, 2023, when Biogen Inc. announced that the U.S. Food and Drug Administration (FDA) approved QALSODY (tofersen) 100 mg/15mL injection for adults with ALS who have a mutation in the superoxide dismutase 1 (SOD1) gene. This approval was granted under the FDA's accelerated approval pathway, based on a reduction in plasma neurofilament light chain (NfL) levels in patients treated with QALSODY.

Segment Covered in Amyotrophic Lateral Sclerosis Market:

By Drug: Rilutek (Riluzole), Edaravone (Radicava), Others.

By Treatment Type: Physical therapy, Speech Therapy, Medication, Respiratory Therapy, Others.

By End-User: Diagnostic Centers, Hospitals, Clinics, Others.

Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/amyotrophic-lateral-sclerosis-market

Key players involved in Amyotrophic Lateral Sclerosis Market:

• Sanofi S.A.
• Brainstorm Cell Therapeutics
• Biogen Inc.
• Bausch Health
• F Hoffmann-la Roche Ltd
• Ionis Pharmaceuticals
• Mylan Pharma
• Sun Pharma
• Orion Pharmaceuticals
• AB Science

*Note:

• Additionally, I wanted to highlight that the full version of the report includes an in-depth analysis of emerging players and startups, which will provide valuable insights into the evolving market landscape and key strategies being adopted.

Regional Analysis:

The Amyotrophic Lateral Sclerosis Market report focuses on six major regions: North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa. The report offers detailed insight into new product launches, new technology evolutions, innovative services, and ongoing R&D. The report discusses a qualitative and quantitative market analysis, including PEST analysis, SWOT analysis, and Porter's five force analysis. The Amyotrophic Lateral Sclerosis Market report also provides fundamental details such as raw material sources, distribution networks, methodologies, production capacities, industry supply chain, and product specifications.

Related Reports:

Epilepsy Drugs Market: https://www.datamintelligence.com/research-report/epilepsy-drugs-market

Anti-Suicide Drugs Market: https://www.datamintelligence.com/research-report/anti-suicide-drugs-market

Salicylic Acid Market: https://www.datamintelligence.com/research-report/salicylic-acid-market

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.